Q-omics provides the consensus-scored GLB1L3 profile across patient tissues and cancer cell-line models. GLB1L3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GLB1L3 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, GLB1L3 RNA expression shows 15,028 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, LUAD, and PCPG as cancer lineages where GLB1L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLB1L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLB1L3 survival associations across molecular data types. GLB1L3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLB1L3 RNA expression–survival associations across cancer types. High GLB1L3 expression shows unfavorable associations in ACC, READ and KIRP, but favorable associations in LUAD, CESC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GLB1L3 RNA expression.
This table summarizes GLB1L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GLB1L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLB1L3 shows lower tumor expression in KIRP, BRCA, COAD and THCA and higher tumor expression in LUAD and LIHC. The LUAD box plot shows higher GLB1L3 RNA expression in tumor versus normal tissue (log2 FC = +2.229, t-test p < 0.001).
This table shows molecular features associated with GLB1L3 in patient tissues and cancer cell lines. In patient samples, GLB1L3 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, GLB1L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
